CCCC NASDAQ
C4 Therapeutics, Inc.
1W: -1.0%
1M: -22.2%
3M: -28.7%
YTD: +52.9%
1Y: +37.2%
3Y: +63.0%
5Y: -94.0%
$2.95
-0.19 (-6.05%)
Weekly Expected Move ±7.7%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
2 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (48)
Catalyst Watch: Microsoft event, FOMC talk, and the finish line for Paramount-Warner Bros.
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Q3 EPS Estimates for C4 Therapeutics Increased by Analyst
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $7.75 Average PT from Analysts
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
12 Health Care Stocks Moving In Friday's Intraday Session
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
Earnings Scheduled For May 12, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $7.75
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?
C4 Therapeutics beats Q4 street views
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of “Moderate Buy” by Brokerages
C4 Therapeutics to Participate in Upcoming March Conferences
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Insider Selling: C4 Therapeutics (NASDAQ:CCCC) Insider Sells $22,200.00 in Stock
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
C4 Therapeutics Sees Unusually High Options Volume (NASDAQ:CCCC)
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss